Latest Caligan Partners LP Stock Portfolio
Caligan Partners LP Performance:
2024 Q3: 1.26%YTD: 15.58%2023: 43.95%
Performance for 2024 Q3 is 1.26%, and YTD is 15.58%, and 2023 is 43.95%.
About Caligan Partners LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Caligan Partners LP reported an equity portfolio of $315.5 Millions as of 30 Sep, 2024.
The top stock holdings of Caligan Partners LP are LQDA, VRNA, EXEL. The fund has invested 25.7% of it's portfolio in LIQUIDIA CORPORATION and 13.1% of portfolio in VERONA PHARMA PLC.
The fund managers got completely rid off ALIMERA SCIENCES INC (ALIM) stocks. They significantly reduced their stock positions in ENANTA PHARMACEUTICALS INC (ENTA), BIOCRYST PHARMACEUTICALS INC (BCRX) and OUTLOOK THERAPEUTICS INC (OTLK). The fund showed a lot of confidence in some stocks as they added substantially to Y-MABS THERAPEUTICS INC (YMAB), MINERALYS THERAPEUTICS INC and AGIOS PHARMACEUTICALS INC (AGIO).
The top stock holdings of Caligan Partners LP are LQDA, VRNA, EXEL. The fund has invested 25.7% of it's portfolio in LIQUIDIA CORPORATION and 13.1% of portfolio in VERONA PHARMA PLC.
The fund managers got completely rid off ALIMERA SCIENCES INC (ALIM) stocks. They significantly reduced their stock positions in ENANTA PHARMACEUTICALS INC (ENTA), BIOCRYST PHARMACEUTICALS INC (BCRX) and OUTLOOK THERAPEUTICS INC (OTLK). The fund showed a lot of confidence in some stocks as they added substantially to Y-MABS THERAPEUTICS INC (YMAB), MINERALYS THERAPEUTICS INC and AGIOS PHARMACEUTICALS INC (AGIO).
Caligan Partners LP Annual Return Estimates Vs S&P 500
Our best estimate is that Caligan Partners LP made a return of 1.26% in the last quarter. In trailing 12 months, it's portfolio return was 60.58%.
New Buys
Additions
| Ticker | % Inc. |
|---|---|
| y-mabs therapeutics inc | 105 |
| mineralys therapeutics inc | 31.56 |
| agios pharmaceuticals inc | 12.63 |
| i mab | 3.69 |
| evolus inc | 1.19 |
Additions to existing portfolio by Caligan Partners LP
Reductions
| Ticker | % Reduced |
|---|---|
| enanta pharmaceuticals inc | -69.08 |
| biocryst pharmaceuticals inc | -43.82 |
| outlook therapeutics inc | -36.26 |
| verona pharma plc | -22.07 |
| liquidia corporation | -21.64 |
| anika therapeutics inc | -0.06 |
Caligan Partners LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| alimera sciences inc | -93,603,500 |
Caligan Partners LP got rid off the above stocks
Sector Distribution
Caligan Partners LP has about 94.9% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 94.9 |
| Others | 5.1 |
Market Cap. Distribution
Caligan Partners LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 59.4 |
| MID-CAP | 33.8 |
| UNALLOCATED | 5.1 |
| MICRO-CAP | 1.6 |
Stocks belong to which Index?
About 69.2% of the stocks held by Caligan Partners LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 69.2 |
| Others | 30.8 |
Caligan Partners LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Caligan Partners LP
Caligan Partners LP has 12 stocks in it's portfolio. LQDA proved to be the most loss making stock for the portfolio. EOLS was the most profitable stock for Caligan Partners LP last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AGIO | agios pharmaceuticals inc | 8.16 | 579,717 | 25,756,800 | added | 12.63 | ||
| ALIM | alimera sciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ANIK | anika therapeutics inc | 11.24 | 1,435,130 | 35,447,700 | reduced | -0.06 | ||
| BCRX | biocryst pharmaceuticals inc | 6.22 | 2,583,580 | 19,635,200 | reduced | -43.82 | ||
| ENTA | enanta pharmaceuticals inc | 1.06 | 322,453 | 3,340,610 | reduced | -69.08 | ||
| EOLS | evolus inc | 11.26 | 2,193,490 | 35,534,500 | added | 1.19 | ||
| EXEL | exelixis inc | 12.55 | 1,525,730 | 39,592,700 | unchanged | 0.00 | ||
| IMAB | i mab | 1.38 | 3,499,330 | 4,339,170 | added | 3.69 | ||
| LQDA | liquidia corporation | 25.74 | 8,118,590 | 81,185,900 | reduced | -21.64 | ||
| OTLK | outlook therapeutics inc | 0.54 | 318,699 | 1,701,850 | reduced | -36.26 | ||
| VRNA | verona pharma plc | 13.10 | 1,436,880 | 41,339,000 | reduced | -22.07 | ||
| YMAB | y-mabs therapeutics inc | 4.98 | 1,195,250 | 15,717,600 | added | 105 | ||
| mineralys therapeutics inc | 3.77 | 981,155 | 11,881,800 | added | 31.56 | |||